Overview of Topelia

The Topelia business model is built on taking our patented Antiviral Triple Therapy (ATT), which combines the existing approved drugs zinc chelate, ivermectin, and doxycycline, to treat coronavirus.

The benefit of using a combination of drugs that have already been approved means that the timeline is greatly reduced, as it starts at Phase 2 clinical trials. Risk is also reduced, as a significant body of data already exists on the ATT component drugs.